KalVista Pharmaceuticals, Inc. (KALV) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KALV Revenue Growth
KALV Revenue Analysis (2014–2025)
As of May 8, 2026, KalVista Pharmaceuticals, Inc. (KALV) generated trailing twelve-month (TTM) revenue of $15.1 million. The most recent quarter (Q2 2026) recorded $13.7 million in revenue, up 860.2% sequentially.
Looking at the longer-term picture, KALV's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $16.1 million in 2019.
When compared to Healthcare sector peers including XOMA (+126.2% YoY), and AGEN (+10.4% YoY). Compare KALV vs XOMA →
KALV Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KALVCurrent | $15M | - | - | - | |
 XOMA | $52M | +126.2% | +12.2% | 21.8% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
KALV Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-187,995,000 | - |
| 2024 | $0 | - | $-86,167,000 | - | $-140,445,000 | - |
| 2023 | $0 | - | $0 | - | $-110,871,000 | - |
| 2022 | $0 | - | $0 | - | $-96,613,000 | - |
| 2021 | $0 | -100.0% | $-41,286,000 | - | $-57,923,000 | - |
| 2020 | $12.7M | -21.3% | $-27,504,000 | -216.7% | $-40,533,000 | -319.4% |
| 2019 | $16.1M | +92.1% | $16.1M | 99.8% | $-29,820,000 | -184.9% |
| 2018 | $8.4M | +458.1% | $8.4M | 99.8% | $-18,705,000 | -222.8% |
| 2017 | $1.5M | -29.5% | $1.5M | 99.2% | $-22,339,000 | -1485.3% |
| 2016 | $2.1M | +18.2% | $2.1M | 99.3% | $-15,181,000 | -711.7% |
See KALV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KALV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KALV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKALV — Frequently Asked Questions
Quick answers to the most common questions about buying KALV stock.
Is KALV's revenue growth accelerating or slowing?
KALV TTM revenue: $15M. YoY growth: N/A. 5-year CAGR: N/A.
What is KALV's long-term revenue growth rate?
KalVista Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is KALV's revenue distributed by segment?
KALV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.